The Role of Gut Microbiota in Inflammatory Bowel Disease

Mechanisms, Therapeutic Targets, and Future Directions


  • Hafsa Khalil Women Medical and Dental College Abbottabad, Pakistan Author
  • Rubab Ahmad Women Medical and Dental College Abbottabad, Pakistan Author
  • Mehr un Nisa Sawar Women Medical and Dental College Abbottabad, Pakistan Author
  • Atizaz Ahmad Saidu Medical College Swat, Pakistan Author
  • Hareera Women Medical and Dental College Abbottabad, Pakistan Author
  • Imran Khan Pak International Medical College, Peshawar, Pakistan Author



Inflammatory Bowel Disease (IBD), chronic inflammatory conditions, digestive tract, gut microbiota, microorganisms, gastrointestinal tract, dysbiosis, microbial diversity, therapeutic targets


Background: The complicated result of immune response dysregulation, genetic predisposition, and external factors combines to cause a condition called inflammatory bowel disease (IBD). An increasing number of studies have lately connected the onset and progression of bowel inflammation to the gut flora.
Aims and Objectives: This study aimed to look at gut function microbiota in IBD, elucidate its mechanisms, identify potential therapeutic targets, and explore future directions in this rapidly evolving field.
Methodology: To examine the function of the gastrointestinal tract A cross-sectional study was carried out at the Pakistan Academy of Medicine and Dentistry (PIMS) in Islamabad between April 2023 and March 2024. We recruited a total of 72 participants who had received a diagnosis of inflammatory bowel illness. (IBD), and we used next-generation sequencing methods to collect stool samples for microbiota characterization. Demographic information, disease characteristics, and dietary habits were assessed through structured questionnaires.
Results: Analysis of stool samples revealed alterations in gut microbiota composition in IBD patients compared to healthy controls, including a reduction in microbial diversity (Shannon Index: 2.8 ± 0.6 in IBD patients vs. 4.2 ± 0.8 in healthy controls) and shifts in the relative abundance of major phyla (Proteobacteria: 25.7% ± 5.2% in IBD patients vs. 12.1% ± 3.5% in healthy controls; Firmicutes: 41.3% ± 8.1% in IBD patients vs. 58.9% ± 7.3% in healthy controls). Dietary elements, illness severity, and gut microbiota composition were linked in IBD patients. Promising anti-inflammatory compounds and regulating the diversity of bacteria were two of the prospective goals for therapy found.
Conclusion: Our research establishes a dysbiotic gut microbiota in IBD and shows how it relates to dietary variables and the severity of the illness. A potential treatment strategy for IBD is to target the gut microbiota, but more investigation is required to fully understand the intricate relationships that exist between the gut microbiota, host characteristics, and environmental effects.
Keywords: Inflammatory Bowel Disease (IBD) refers to a group of chronic inflammatory conditions that affect the digestive tract. The gut microbiota, which refers to the community of microorganisms that reside in the gastrointestinal tract, plays a significant role in the development and progression of IBD, dysbiosis, microbial diversity, disease severity, therapeutic targets


Download data is not yet available.

Author Biographies

  • Hafsa Khalil, Women Medical and Dental College Abbottabad, Pakistan


  • Rubab Ahmad, Women Medical and Dental College Abbottabad, Pakistan


  • Mehr un Nisa Sawar, Women Medical and Dental College Abbottabad, Pakistan


  • Atizaz Ahmad, Saidu Medical College Swat, Pakistan


  • Hareera, Women Medical and Dental College Abbottabad, Pakistan


  • Imran Khan, Pak International Medical College, Peshawar, Pakistan



⦁ Santana PT, Rosas SL, Ribeiro BE, Marinho Y, de Souza HS. Dysbiosis in inflammatory bowel disease: pathogenic role and potential therapeutic targets. International journal of molecular sciences. 2022 Mar 23;23(7):3464.

⦁ Lane ER, Zisman TL, Suskind DL. The microbiota in inflammatory bowel disease: current and therapeutic insights. Journal of inflammation research. 2017 Jun 10:63-73.

⦁ Zuo T, Ng SC. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Frontiers in microbiology. 2018 Sep 25;9:365492.

⦁ Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The gut microbiota in inflammatory bowel disease. Frontiers in cellular and infection microbiology. 2022 Feb 22;12:733992.

⦁ Yuan S, Wang KS, Meng H, Hou XT, Xue JC, Liu BH, Cheng WW, Li J, Zhang HM, Nan JX, Zhang QG. The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:114893.

⦁ Alshehri D, Saadah O, Mosli M, Edris S, Alhindi R, Bahieldin A. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. Bosnian Journal of Basic Medical Sciences. 2021 Jun;21(3):270.

⦁ Mukherjee S, Joardar N, Sengupta S, Babu SP. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: lessons from recent findings. The Journal of nutritional biochemistry. 2018 Nov 1;61:111-28.

⦁ Katsanos KH, Papadakis KA. Inflammatory bowel disease: updates on molecular targets for biologics. Gut and Liver. 2017 Jul;11(4):455.

⦁ Amoroso C, Perillo F, Strati F, Fantini M, Caprioli F, Facciotti F. The role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation. Cells. 2020 May 16;9(5):1234.

⦁ Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, Che T, Zhang C. Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019 Aug 13;8(3):126.

⦁ Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M. Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives. World journal of gastrointestinal oncology. 2022 Mar 3;14(3):547.

⦁ Yue B, Yu ZL, Lv C, Geng XL, Wang ZT, Dou W. Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease. World Journal of Gastroenterology. 2020 Aug 8;26(30):4378.

⦁ Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. InMayo Clinic Proceedings 2019 Jan 1 (Vol. 94, No. 1, pp. 155-165). Elsevier.

⦁ Michalak A, Mosińska P, Fichna J. Common links between metabolic syndrome and inflammatory bowel disease: current overview and future perspectives. Pharmacological Reports. 2016 Aug 1;68(4):837-46.

⦁ Ahlawat S, Kumar P, Mohan H, Goyal S, Sharma KK. Inflammatory bowel disease: tri-directional relationship between microbiota, immune system and intestinal epithelium. Critical Reviews in Microbiology. 2021 Mar 4;47(2):254-73.

⦁ Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Frontiers in medicine. 2021 Dec 20;8:765474.

⦁ Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune network. 2017 Feb;17(1):25.

⦁ Weisshof R, El Jurdi K, Zmeter N, Rubin DT. Emerging therapies for inflammatory bowel disease. Advances in therapy. 2018 Nov;35:1746-62.

⦁ Wang M, Shi J, Yu C, Zhang X, Xu G, Xu Z, Ma Y. Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds?. Frontiers in Immunology. 2023 Dec 14;14:1298186.

⦁ Castro-Dopico T, Colombel JF, Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Current opinion in pharmacology. 2020 Dec 1;55:90-8.






Research Articles


How to Cite

Khalil H, Rubab Ahmad, Sawar M un N, Ahmad A, Hareera, Khan I. The Role of Gut Microbiota in Inflammatory Bowel Disease: Mechanisms, Therapeutic Targets, and Future Directions. IRABCS [Internet]. 2024 Jun. 30 [cited 2024 Jul. 20];2(1):85-90. Available from:

Similar Articles

1-10 of 15

You may also start an advanced similarity search for this article.